News Moberg Pharma AB

Equities

MOB

SE0020353928

Market Closed - Nasdaq Stockholm Other stock markets 11:29:39 2024-04-18 am EDT			5-day change	1st Jan Change
27.16 ^SEK	-7.93%		-24.43%	+78.68%

Apr. 08	Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	CI
Feb. 26	Certain Ordinary Shares of Moberg Pharma AB are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Notice of Annual General Meeting in Moberg Pharma AB (publ)	Apr. 12	AQ
Moberg Pharma Annual report for 2023	Apr. 12	AQ
Moberg Pharma : Corporate Governance Report 2023	Apr. 12	PU
Moberg Pharma : Application submitted to include an additional terbinafine supplier	Apr. 08	PU
Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	Apr. 08	CI
Certain Ordinary Shares of Moberg Pharma AB are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
The Nomination Committee's proposal to the Annual General Meeting 2024	Feb. 19	AQ
Moberg Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 13	CI
Moberg Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication	Feb. 07	AQ
Moberg Pharma's Interim report January - September 2023	Nov. 07	AQ
Moberg Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Moberg Pharma strengthens the organization	Nov. 07	AQ
Moberg Pharma Announces Leadership Changes	Nov. 07	CI
Moberg Pharma's Nomination Committee appointed	23-10-17	AQ
Moberg Pharma AB Appoints Nomination Committee	23-10-17	CI
MOBERG PHARMA HAS COMPLETED ENROLLMENT TO THE PHASE 3 STUDY FOR MOB-015 IN NORTH AMERICA	23-10-09	AQ
Bulletin from Moberg Pharma's Extraordinary General Meeting	23-10-09	AQ
Moberg Pharma Completes Patient Recruitment for North American Trial of Nail Fungus Treatment	23-10-06	MT
Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America	23-10-06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Moberg Pharma AB

Equities

MOB

SE0020353928

Summary

Filters